Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
By: Nasdaq / GlobeNewswire - 24 May 2019 | Back to overview list |
|
BOTHELL, Wash., May 24, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee of Alder’s Board of Directors granted a non-qualified stock option to purchase an aggregate of 50,000 shares of Alder’s common stock to a new employee under Alder’s 2018 Inducement Award Plan, effective May 21, 2019. The stock option will vest with respect to 25% of the shares underlying the option one year after the employee’s employment start date and the remaining 75% of the shares underlying the option will vest in equal monthly installments over the 36 month period following the one year anniversary of the employee’s employment start date, subject to the employee’s continued service to Alder through each relevant vesting date. The option has a ten year term and an exercise price of $11.35 per share, which is equal to the closing price of Alder’s common stock on May 21, 2019. The stock option was granted as an inducement material to the employee’s entering into employment with Alder in accordance with Nasdaq Listing Rule 5635(c)(4). About Alder BioPharmaceuticals, Inc. Investor Relations Contact: Media Contact: |
||
|
||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |